Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares traded -0.06% lower at $16.29 on Wall Street last session.
TEVA stock price is now 15.88% away from the 50-day moving average and 44.46% away from the 200-day moving average. The market capitalization of the company currently stands at $18.26B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $14, JP Morgan recently Upgraded its rating from Underweight to Neutral for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). On February 12, 2024, Piper Sandler Upgraded its previous ‘Neutral’ rating to ‘Overweight’ on the stock increasing its target price from $12 to quote $19, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Weiss Amir, Chief Accounting Officer sold 12,635 shares of the company’s stock on May 16 ’24. The stock was sold for $210,377 at an average price of $16.65. Upon completion of the transaction, the Chief Accounting Officer now directly owns 5,179 shares in the company, valued at $84365.91. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’24, Chief Accounting Officer Weiss Amir sold 15,500 shares of the business’s stock. A total of $260,417 was realized by selling the stock at an average price of $16.80. This leaves the insider owning 17,814 shares of the company worth $0.29 million. A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $7.09 and a high of $17.13. As of last week, the company has a debt-to-equity ratio of 2.74, a current ratio of 0.89, and a quick ratio of 0.61.
According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at 0.56, beating analysts’ expectations of 0.52 by 0.04. This compares to -$0.23 EPS in the same period last year. The net profit margin was -2.88% and return on equity was -6.08% for TEVA. The company reported revenue of $3.82 billion for the quarter, compared to $3.66 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.32 percent. For the current quarter, analysts expect TEVA to generate $4.04B in revenue.
